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The definition and classification for chronic kidney disease
was proposed by the National Kidney Foundation Kidney
Disease Outcomes Quality Initiative (NKF-KDOQI) in 2002 and
endorsed by the Kidney Disease: Improving Global Outcomes
(KDIGO) in 2004. This framework promoted increased
attention to chronic kidney disease in clinical practice,
research and public health, but has also generated debate.
It was the position of KDIGO and KDOQI that the definition
and classification should reflect patient prognosis and that an
analysis of outcomes would answer key questions underlying
the debate. KDIGO initiated a collaborative meta-analysis and
sponsored a Controversies Conference in October 2009 to
examine the relationship of estimated glomerular filtration
rate (GFR) and albuminuria to mortality and kidney
outcomes. On the basis of analyses in 45 cohorts that
included 1,555,332 participants from general, high-risk, and
kidney disease populations, conference attendees agreed
to retain the current definition for chronic kidney disease
of a GFR o60ml/min per 1.73m2 or a urinary albumin-to-
creatinine ratio 430mg/g, and to modify the classification
by adding albuminuria stage, subdivision of stage 3, and
emphasizing clinical diagnosis. Prognosis could then be
assigned based on the clinical diagnosis, stage, and other key
factors relevant to specific outcomes. KDIGO has now
convened a workgroup to develop a global clinical practice
guideline for the definition, classification, and prognosis
of chronic kidney disease.
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In 2002, the National Kidney Foundation’s Kidney Disease
Outcomes Quality Initiative (KDOQI) introduced a con-
ceptual model for the definition and classification of chronic
kidney disease.1,2 The model included antecedents associated
with increased risk for development of chronic kidney
disease, earlier stages of disease that could progress to later
stages or lead to complications, and kidney failure as the end-
stage (Figure 1). Chronic kidney disease was defined based on
the presence of kidney damage or glomerular filtration rate
(GFR o60 ml/min per 1.73 m2) for X3 months, irrespective
of cause, and was classified into five stages based on the level
of GFR. This framework advanced a uniform nomenclature
for chronic kidney disease, objective diagnostic criteria
irrespective of cause that could be assessed in most cases
from readily available clinical laboratory data, and a simple
classification scheme linked to a clinical action plan. In 2004,
Kidney Disease: Improving Global Outcomes (KDIGO)
endorsed this framework with minimal modifications.3 In
less than a decade, this framework has had enormous effects
on clinical practice, research and public health policy.
During this time, there has also been increasing recogni-
tion of limitations of the definition and classification, leading
to a heated debate and calls for revisions, mainly in
nephrology subspecialty journals. This debate reflects critical
self-appraisal of changing knowledge and practice within the
discipline and provides opportunities for improvement.
However, revisions should be based on a carefully defined
rationale, should follow a defined process, and in line with
policies for disease definitions and classification in other
medical disciplines, should use the best-available evidence.
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The ultimate goal is that application of a definition and
classification for kidney disease will lead to improved patient
outcomes.
The leadership of KDIGO, with the endorsement of
KDOQI, convened a Controversies Conference to provide a
forum for an open discussion.4 A structured format was used
to examine the validity of the existing system, as well as to
evaluate proposed alternatives. It was the position of KDIGO
and KDOQI that the definition and classification of chronic
kidney disease should reflect patient prognosis and that a
comprehensive analysis of outcomes by estimated GFR
(eGFR) and albuminuria would shed light on the key
underlying questions. The Conference was held in London
in October 2009 and was attended by 98 people, including
representatives from 50 cohorts with data on estimated
eGFR, albuminuria, and mortality and kidney outcomes. By
the end of the conference, participants reached consensus on
a proposal to maintain the definition and revise the
classification of chronic kidney disease. The purpose of this
report is to describe the controversy, the conference, the data,
and the proposed revisions and their implications.
THE CONTROVERSY
In clinical practice, clinicians have the opportunity to make a
detailed clinical assessment over time, including history,
physical examination, and laboratory and imaging studies, to
establish the clinical diagnosis of chronic kidney disease,
including a search for its cause and determination of the
pathological features. In epidemiological studies, kidney
damage is usually ascertained as albuminuria estimated from
the albumin-to-creatinine ratio (ACR) in a random (‘spot’)
urine sample, GFR is estimated from serum creatinine, all
measurements are made at a single point in time, and clinical
diagnosis is not ascertained. Application of only these two
criteria leads to a simple two-dimensional grid, in which all
people with urine ACR X30 mg/g (the threshold commonly
accepted for ‘microalbuminuria’) or eGFR o60 ml/min per
1.73 m2 are defined as having chronic kidney disease, and
staged according to the level of GFR (Figure 2). When
applied in the US population studies,B12% (25 million) are
estimated to have chronic kidney disease, whereas o0.2%
(4500,000) have kidney failure treated by dialysis or
transplantation.5,6 The prevalence of chronic kidney disease
is especially high in the elderly, affecting 440% of people
over the age of 70 years. Similar prevalence estimates have
been reported around the globe, and some reports note an
increasing prevalence over time.5,7–9 Numerous studies show
that chronic kidney disease, defined according to these
criteria, is a risk factor for cardiovascular disease10 and is
associated with increased costs of care.11 These prevalence
estimates are not higher than for other chronic diseases
primarily affecting the elderly in the United States and
leading to an increased risk for cardiovascular disease
Death
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Figure 1 |Conceptual model (updated). This diagram presents the continuum of development, progression, and complications of chronic
kidney disease.1,2 Green circles represent stages of chronic kidney disease; aqua circles represent potential antecedents, lavender circles
represent consequences, and thick arrows between ellipses represent risk factors associated with the development, progression, and
remission of chronic kidney disease. ‘Complications’ refers to all complications of chronic kidney disease and interventions for its treatment
and prevention, including complications of decreased glomerular filtration rate (GFR) and cardiovascular disease.
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and NHANES III (1988 –1994)
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5 Kidneyfailure <15
0.0
>30
Mild
Figure 2 |Percentage of US population by estimated
glomerular filtration rate (eGFR) and albuminuria category
using the definition and classification of chronic kidney
disease (Kidney Disease Outcomes Quality Initiative (KDOQI)
2002 and Kidney Disease: Improving Global Outcomes
(KDIGO) 2004) and prevalence estimates from National Health
and Nutrition Examinations Survey III (NHANES III;
1988–1994) based on Modification of Diet in Renal Disease
(MDRD) Study eGFR and standardized serum creatinine.
Albuminuria ascertained by single measurement of albumin-to-
creatinine ratio. Values in cells do not total to 100% because
of rounding.
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mortality, such as hypertension (33.3%, 73.6 million),
diabetes (10.6%, 23.4 million), and clinical cardiovascular
disease (36.3%, 80.0 million).12
Rising prevalence, poor outcomes, and high costs of
chronic kidney disease have led to its recognition as a public
health threat.13 Fundamentally, this recognition represents a
paradigm shift in the perception of kidney disease, especially
for nephrologists, from a life-threatening condition affecting
few people who require treatment by dialysis or transplanta-
tion to a common condition that is the target for prevention,
early detection, and management by non-nephrologist
physicians and public health agencies.14 However, given the
wide implications, concerns over the definition and classifi-
cation of chronic kidney disease have also arisen.
The perceived limitations focus on several areas (Table 1).4
The high prevalence estimates of early stages of disease,
especially compared with later stages, may represent over-
diagnosis and misdiagnosis of kidney disease, particularly in
the elderly, leading to the potential for overuse of sub-
specialty resources. Use of the term ‘disease’ to describe
asymptomatic laboratory conditions, rather than ‘pre-
disease’ or ‘risk factor’ may cause unnecessary concern in
patients and clinicians. Methodological issues in GFR
estimation and ascertainment of albuminuria may not be
refined well enough to permit their use in clinical laboratory
reporting or screening. The classification system may lack
coherence; stage does not reliably predict prognosis. Finally,
the threshold values for eGFR and urine ACR, without other
evidence of disease, may not be appropriate for disease
definition, especially when applied without regard to age, sex,
and race.
A number of alternative proposals for the definition and
classification have been suggested.4 Some have proposed a
lower eGFR threshold (30 or 45 vs 60 ml/min per 1.73 m2), a
higher urine ACR threshold (300 vs 30 mg/g), or age-specific
thresholds. These modifications to the definition would limit
the identification of chronic kidney disease to fewer
individuals with more severe disease and a higher risk for
adverse outcomes. Some have proposed combining stages 1–2
and subdividing stage 3 because of the nonlinear relationship
between GFR estimated from serum creatinine and risk.
Others have proposed incorporating albuminuria into disease
staging across all levels of GFR. This would enable greater
stratification of risk, as a growing body of evidence suggests
that albuminuria is strongly associated with the risk of
adverse outcomes independently of GFR, even in general
populations.
It is instructive to compare the current classification of
chronic kidney disease with classification systems for other
diseases. The chronic kidney disease classification is based
primarily on severity of functional impairment, as assessed
from the level of GFR. Other possible axes for classification of
disease include cause, structure, symptoms, treatment, and
prognosis. Nephrology has well-developed systems of classi-
fication based on cause and pathology of kidney disease.
Symptoms in chronic kidney disease are nonspecific and
uncommon until late stages and thus are not useful for
classification. Classification of chronic kidney disease by
treatment has limited utility, as there are few treatments
for the underlying clinical diagnosis, and most treatments
are directed at preventing progression or complications. The
KDIGO Conference in 2004 suggested adding a notation to
identify treatment by dialysis (D) or transplantation (T).3
Prognosis is central to most of the concerns in the current
debate, but is not captured well in the current classification
system. Prognosis is important to patients, clinicians, public
health, and health policy, and better information on
prognosis could inform the debate. In particular, estimates
of the risks for adverse events based on eGFR and urine ACR
could enable assessment of the current definition and
classification and determine what, if any, revisions to the
current system are appropriate.
THE CONFERENCE
The scope of the Conference was to address the following
topics: What are the key outcomes of chronic kidney disease?
What progress has been made in testing for chronic kidney
disease, focusing on eGFR and albuminuria? What are the key
factors determining prognosis? Should the current classifica-
tion (based on eGFR) be modified to include additional
factors associated with prognosis? Should the current
definition be modified?
The Planning Committee structured critical aspects of the
debate on the definition and classification of chronic kidney
disease to focus on prognosis. The goals were to assemble data
on prognosis from a wide variety of cohorts and to use a
transparent process and rigorous methods to analyze these
data to answer five specific questions about the definition and
classification (Box 1). The Planning Committee concluded
that there are insufficient data at this time to answer questions
about the causes of albuminuria and decreased GFR in the
elderly, whether these findings represent ‘aging’ vs pathological
processes, the benefit of screening for early detection of
disease vs the harm of ‘disease’ labeling, and costs. Thus,
these issues were not included in the Conference agenda.
Table 1 | Recent concerns with KDOQI definition and
classification
Overdiagnosis Prevalence of earlier stages of chronic kidney
disease is too high compared with incidence of
treated kidney failure, especially in the elderly
Terms Earlier stages of chronic kidney disease should be
labeled ‘risk factor’ or ‘pre-disease’ rather than
‘disease’
Methods GFR estimation compared with measured GFR.
Spot urine albumin-to-creatinine ratios compared
with timed albumin excretion rates. Single vs
repeated measurements over 3 months
Coherence Some patients at earlier stages are at higher risk
of adverse outcomes than those at later stages
Threshold values GFR and albuminuria vary according to age, sex,
or race
Abbreviations: GFR, glomerular filtration rate; KDOQI, Kidney Disease Outcomes
Quality Initiative.
Source: Eckardt et al.4
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Although the lack of data to answer these latter questions is
an important shortcoming, there are few diseases for which
the definitions and classification are based on such data.
The Planning Committee identified all-cause and cardi-
ovascular disease mortality and kidney outcomes as the
highest priority outcomes for this analysis. In addition to
kidney failure treated by dialysis or transplantation (end-
stage renal disease), acute kidney injury was included,
because it is increasingly recognized as a complication as
well as a cause of chronic kidney disease.15,16 Kidney disease
progression based on eGFR decline was included because of
its clinical importance, owing to a high risk of complications
and potential for further progression to kidney failure.
The Planning Committee considered three types of
cohorts: general population cohorts, high-risk cohorts
(subjects selected because of hypertension, diabetes, clinical
cardiovascular disease, or a history of kidney disease), and
chronic kidney disease cohorts (subjects selected because of
chronic kidney disease), and identified investigators with
access to published or unpublished data from research studies
or clinical populations. Cohorts were identified from a
systematic search of published articles from general popula-
tion cohorts and from Committee members’ knowledge of
published and unpublished data from all three types of
cohorts. The search was enhanced by calls for participation at
the World Congress of Nephrology in Milan (May, 2009), a
published position statement of KDOQI and KDIGO,4 and
an announcement on the KDIGO website.17
A survey was conducted to determine ascertainment of
eGFR, albuminuria, and key clinical outcomes. Serum
creatinine assay calibrated to isotope dilution mass spectro-
metry was preferred for estimation of GFR using the
Modification of Diet in Renal Disease (MDRD) Study
equation for standardized creatinine,18 but calibration
methods were not uniform. ACR was the preferred measure
of albuminuria,19 but dipstick urine protein and total urine
protein-to-creatinine ratio were accepted if ACR was not
available. Investigators from cohorts with adequate baseline
measures and number of events in follow-up were invited to
perform predefined analyses developed by the Analytic Team
led by two members of the Planning Committee (PEdJ and
JC). Investigators who agreed to perform the analyses and
share results before the Conference were invited to attend.
The Analytic Team assembled data from individual cohorts
using a standardized format for ‘slides’. For cohorts with
sufficient number of outcomes that agreed to pool data, the
Analytic Team performed a series of meta-analyses. A total of
1704 slides from individual cohorts and 454 slides from the
meta-analyses were distributed to all meeting participants at
the beginning of the Conference.
The Conference included introductory remarks on the
current definition and classification of chronic kidney
disease, limitations of the current scheme, and the questions
to be answered. Updates were presented on progress in
standardization of creatinine, cystatin C and urine albumin
assays, GFR-estimating equations, assessment of albuminuria,
and novel outcomes of chronic kidney disease. Preliminary
results from the meta-analyses and application of these
results to the questions of interest were presented by the
Analytic Team in plenary sessions and discussed further in
breakout sessions. In the final plenary session, attendees were
asked to participate in a non-binding vote on each question.
There was agreement by greater than two-thirds of
conference participants on all questions. At the end of
the Conference, attendees were invited to participate in an
ongoing research project, the Chronic Kidney Disease
Prognosis Consortium, led by the Analytic Team, to develop
manuscripts from the final meta-analyses and to design new
analyses to answer additional questions about prognosis of
chronic kidney disease. The agenda of the conference and
slide presentations can be accessed at the KDIGO website.17
THE DATA
Analytic plan
For the analysis plan, the ‘a priori’ hypothesis was that both
eGFR and albuminuria would be associated with mortality
and kidney disease outcomes, independent of traditional
cardiovascular risk factors and independent of each other,
and despite inclusion of diverse study populations. The
Analytic Team provided definitions of study populations and
outcomes as defined above, predictors (eGFR and measures
of albuminuria), adjustment variables (age, sex, race, history
of clinical cardiovascular disease and cardiovascular disease
risk factors (smoking, systolic blood pressure, diabetes, and
serum total cholesterol), and treatment assignment for
clinical trials), and statistical code for survival and logistic
regression analyses using continuous and categorical defini-
tions of predictor variables.
For continuous analysis, splines for eGFR at multiple
points were used to allow for nonlinearity. For the general
population and high-risk population, comparisons were
made with reference points of eGFR of 95 ml/min per
1.73 m2 and ACR of 5 mg/g. These values were considered
optimal, as higher values of eGFR are associated with higher
risk, presumably because of confounding from chronic
conditions associated with decreased creatinine generation,
and urine ACR even below the threshold for microalbumi-
nuria is already associated with increased risk. For the
Box 1 | Prognosis as a tool: questions for the conference to
answer
Definition
Should the threshold value for eGFR be lower than 60ml/min per 1.73m2
or differ by age 465 years?
Should the threshold value for albuminuria be higher than 30mg/g or
differ by age 465 years?
Classification
Should stages 1–2 be combined, divided by level of albuminuria, or both?
Should stage 3 be divided by eGFR o45ml/min per 1.73m2, divided by
level of albuminuria, or both?
Should stage 4 be divided by level of albuminuria?
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chronic kidney disease population, there were insufficient
events at the reference points; hence, relative risks were
computed per 15 ml/min per 1.73 m2 lower eGFR and
eightfold higher ACR or protein-to-creatinine ratio. Analyses
were performed for interactions of eGFR and ACR and of
eGFR vs age as a continuous variable. Additional analyses
were performed stratified by age o65 or X65 years.
For categorical analysis, eGFR and albuminuria were
classified into more categories than that used in the chronic
kidney disease definition and classification (eight categories
for eGFR and five categories for albuminuria, not all
categories were reported for each population). For the
general population and high-risk population, mortality
comparisons were made with a reference group with eGFR
90–104 ml/min per 1.73 m2 and ACR o10 mg/g or dipstick
negative, and kidney outcome comparisons were made with a
reference group with eGFR 460 ml/min per 1.73 m2 and
ACRo30 mg/g or dipstick negative or trace. For the chronic
kidney disease population, comparisons were made with a
reference group with eGFR 45–75 ml/min per 1.73 m2 and
ACR o30 mg/g, dipstick negative or trace, or protein-to-
creatinine ratioo50 mg/g. Heterogeneity among cohorts was
investigated in categorical and continuous analyses using
standard meta-analytic methods.
Study populations
Altogether, 90 cohorts were invited to participate, 69
completed the survey and 53 completed the request analyses
(Figure 3). A total of 45 cohorts, including 1,555,332 people,
were included in the meta-analyses, grouped into four study
populations: a general population with ascertainment of
albuminuria as ACR, a general population with ascertain-
ment of albuminuria by dipstick, a high-risk population, and
a chronic kidney disease population. Table 2 shows the
number of events for each outcome in each population,
stratified by age. In studies that reported multiple outcomes,
cardiovascular disease mortality accounted for approximately
one-third of all-cause mortality, and there were fewer kidney
Identified by planning
committee (90)
Did not complete survey (21)
Completed survey
(69)
Excluded because of insufficient data or unable
to analyze data for the conference (16)
Completed analysis
(53)
Unable to provide data for the meta-analysis (8)
AGES-Reykjavik/CAN-CARE/CAN-Prevent/CRIC/OFUS/
predictors of ESRD in T1DM/ Prevalence of CKD in veterans/
Tromso
Included in meta-
analysis (45*)
N=1,555,332
High risk
(10)
ADVANCE/AKDN
ACR/CARE/
KEEP/KP Hawaii/
MRFIT/
ONTARGET/Pima/
TRANSCEND/
ZODIAC
N=266,975 
General
population
dipstick
(10)
AKDN DIP/
AusDiab DIP/
Beaver Dam/
ESTHER/MRC
Older People/
Ohasama/Okinawa
83/ Okinawa 93/
Severance/Taiwan
N=1,239,447 
General
population
ACR
(14)
ARIC/AusDiab
ACR/ Beijing/CHS/
COBRA/
Framingham/
Gubbio/HUNT/
MESA/NHANES
III/PREVEND/
Rancho Bernardo/
REGARDS/
ULSAM
N=105,872 
Chronic
kidney
disease
(14)
AASK/British
Columbia/CRIB/
Grampian ACR/
Grampian PCR/
MASTERPLAN/
MDRD/
NephroTest/
RENAAL/STENO/
MMKD/REIN/
REIN-2/KP
Northwest
N=21,688 
Figure 3 | Flow diagram of cohorts. *Three cohorts (AKDN, AusDiab, Grampian) were divided into two subcohorts for meta-analysis
according to ascertainment of albuminuria with variable overlap between subcohorts. Note: The study name expansions are provided in the
Appendix.
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outcomes than deaths. As expected, in cohorts that reported
acute kidney injury or in which kidney disease progression
could be computed, these events were more numerous than
end-stage renal disease events. This report summarizes
selected results on mortality and kidney outcomes from the
general population. Detailed presentations on all four
populations are being reported in this issue of Kidney
International20–22 and elsewhere.23
Summary of results from meta-analyses
Figures 4 and 5 summarize the pooled relative risks of
varying levels of eGFR and albuminuria, expressed as
continuous or categorical variables, respectively, for all
five outcomes. The relative risk for each eGFR and urine
ACR combination represents the point estimate from a
meta-analysis. The analyses are complimentary and provide a
comprehensive description of the joint associations of these
two variables with risk. Several key findings relate to the
questions in Box 1.
First, the incidence rates were higher for mortality than
kidney outcomes, but the risk relationships have a similar
shape (Figure 4) and color pattern (Figure 5) for all
outcomes, with higher relative risks associated with lower
eGFR and higher levels of albuminuria, suggesting that
groups at increased risk for one outcome are at increased risk
for all outcomes. In general, the relative risks are higher for
kidney outcomes than for mortality, reflecting a greater
specificity of association of eGFR and ACR with these
outcomes. Not surprisingly, measures of kidney disease are
more dominant factors in kidney outcomes than in mortality
Table 2 | Number of outcomes (% of outcomes in age o and X65 years) in the meta-analysis by population
Population All-cause mortality
Cardiovascular
disease mortality
Kidney
failure (ESRD)
Acute kidney
injury (AKI)
Kidney disease
progression
General population ACR 11,209 (21.1, 78.9) 3823 (15.0, 85.0) 147 (36.7, 63.3) 427 (38.9, 61.1) 173 (26.0, 74.0)
General population dipstick 35,042 (30.9, 69.1) 5980 (19.6, 80.4) 713 (58.8, 41.2) 3438 (33.2, 66.8) 4624 (27.1, 72.9)
High risk 16,009 (52.2, 47.8) 5656 (59.5, 40.5) 1319 (71.8, 28.2) 1074 (37.3, 62.7) 6347 (35.3, 64.7)
Chronic kidney disease 4374 (26.4, 81.6) NA 4157 (62.8, 36.2) NA NA
Abbreviations: ACR, albumin-to-creatinine ratio; AKI, acute kidney injury; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; ICD-9, international
classification of disease-9; NA, not available.
Definitions: Cardiovascular disease mortality was defined as death due to myocardial infarction, heart failure, sudden cardiac death or stroke. ESRD was defined as initiation of
dialysis or transplantation or death coded as due to kidney disease other than AKI. AKI was defined as ICD-9 code 584 as primary or additional discharge code. Kidney disease
progression was defined as an average annual decline in eGFR during follow-up of at least 2.5ml/min per 1.73m2 per year and a last eGFR value ofo45ml/min per 1.73m2,
independent of the level of baseline eGFR. The average annual decline in eGFR was calculated as last available eGFR minus baseline eGFR divided by follow-up time (in years,
minimum 2) between the two observations.
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Figure 4 | Summary of continuous meta-analysis (adjusted relative risk (RR)) for general population cohorts with albumin-to-
creatinine ratio (ACR). Mortality is reported for general population cohorts assessing albuminuria as urine ACR. Kidney outcomes are
reported for general population cohorts assessing albuminuria as either urine ACR or dipstick. Estimated glomerular filtration rate (eGFR) is
expressed as a continuous variable. The three lines represent urine ACR of o30mg/g or dipstick negative and trace (blue), urine ACR
30–299mg/g or dipstick 1þ positive (green), and urine ACR X300mg/g or dipstick X2þ positive (red). All results are adjusted for
covariates and compared with reference point of eGFR of 95ml/min per 1.73m2 and ACR ofo30mg/g or dipstick negative (diamond). Each
point represents the pooled relative risk from a meta-analysis. Solid circles indicate statistical significance compared with the reference
point (Po0.05); triangles indicate non-significance. Red arrows indicate eGFR of 60ml/min per 1.73m2, threshold value of eGFR for the
current definition of chronic kidney disease (CKD). HR, hazards ratio; OR, odds ratio.
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outcomes. Second, there is a graded increase in risk for
higher levels of albuminuria categories, independent of
eGFR, without an apparent threshold value. Increased
relative risk is statistically significant for urine ACR
430 mg/g for mortality and kidney outcomes, even when
GFR is 460 ml/min per 1.73 m2, consistent with the current
threshold value for albuminuria (430 mg/g) as a marker of
kidney damage. Increased relative risk at urine ACR of
10–29 mg/g is also apparent, suggesting that levels below the
threshold may also warrant increased attention. Third, within
each category of albuminuria, the risk for all outcomes is
relatively constant between eGFR of 75 and 105 ml/min per
1.73 m2, with a suggestion of a U-shaped curve for some
outcomes. Even for the group with the lowest value of
albuminuria, the increased relative risk for all outcomes
is significant for eGFR of 60 ml/min per 1.73 m2 in the
continuous analysis and in the range of 45–59 ml/min per
1.73 m2 for the categorical analysis, consistent with the
current threshold value of GFR for the definition of chronic
kidney disease (o60 ml/min per 1.73 m2). Fourth, in the
range of eGFR 30–59 ml/min per 1.73 m2, there is a steep rise
in risk with lower eGFR, consistent with suggestions to
subdivide stage 3 into two stages. In the range of eGFR
X60 ml/min per 1.73 m2, the risk for most outcomes is
higher for lower eGFR between 60 and 74 ml/min per
1.73 m2, which does not support the suggestion to combine
stages 1 and 2. Before making a change, it would be prudent
to re-examine this issue with improved GFR estimation
equations, as the MDRD Study equation is known to be
biased in this range, compared with measured GFR, and less
accurate than the new Chronic Kidney Disease Epidemiology
equation.24 In addition, non-GFR determinants of serum
creatinine may blunt the risk relationship in this range of
GFR, as evidenced by steeper risk relationship with eGFR
computed from cystatin C than estimated (data not shown).
Fifth, the predictive ability of albuminuria at levels of eGFR,
as previously noted by others,25–31 supports the suggestion to
add albuminuria stages at all GFR stages. Although there is a
tendency for the relative risks for higher levels of albuminuria
to converge at low eGFR, most subjects at very low eGFR had
higher levels of albuminuria, and tests for interactions
between eGFR and albuminuria were not significant. Sixth,
age-stratified analyses showed qualitatively similar patterns in
subjects with age o65 and X65 years. In general, incidence
rates were higher in older subjects, whereas relative risks were
higher in younger individuals, as is the pattern for
cardiovascular disease risk factors. The interaction between
eGFR and age as a continuous variable was significant in
some cohorts, but was not consistent. Table 3 shows the
adjusted relative risks for all outcomes stratified by age for
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Figure 5 | Summary of categorical meta-analysis (adjusted relative risk (RR)) for general population cohorts with albumin-to-
creatinine ratio (ACR). Mortality is reported for general population cohorts assessing albuminuria as urine ACR. Kidney outcomes are
reported for general population cohorts assessing albuminuria as either urine ACR or dipstick. Estimated glomerular filtration rate
(eGFR) and albuminuria are expressed as categorical variables. All results are adjusted for covariates and compared with the reference
cell (Ref). Each cell represents a pooled relative risk from a meta-analysis; bold numbers indicate statistical significance at Po0.05. Incidence
rates per 1000 person-years for the reference cells are 7.0 for all-cause mortality, 4.5 for cardiovascular disease mortality, 0.04 for kidney
failure, 0.98 for acute kidney injury (AKI), and 2.02 for kidney disease progression. Absolute risk can be computed by multiplying the relative
risks in each cell by the incidence rate in the reference cell. Colors reflect the ranking of adjusted relative risk. The point estimates for
each cell were ranked from 1 to 28 (the lowest RR having rank number 1, and the highest number 28). The categories with rank numbers
1–8 are green, rank numbers 9–14 are yellow, the rank numbers 15–21 are orange, and the rank numbers 22–28 are colored red.
(For the outcome of kidney disease progression, two cells with RR o1.0 are also green, leaving fewer cells as orange.)
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the category of eGFR of 45–59 ml/min per 1.73 m2 and
optimal albuminuria, compared with the reference group.
With the exception of all-cause mortality, the relative hazards
are similar above and below the age of 65 years. Overall, these
data do not support the suggestion for age-specific GFR
thresholds for the definition of chronic kidney disease.
Finally, numerical estimates for heterogeneity were high, but
qualitative results were generally consistent across cohorts.
These data suggest that the overall pattern of relative risks
that we observed was consistent across most cohorts.
In general, results from the other populations were similar
to the general population with albuminuria ascertained by
ACR, with a few differences. In the general population with
albuminuria ascertained by dipstick, the U-shaped relation-
ship between eGFR and mortality was more prominent and
‘shifted to the left.’ In contrast, in the high-risk population,
the U-shaped curve relationship between eGFR and mortality
was less apparent. The relationship between albuminuria and
mortality was similar in all three populations. In the chronic
kidney disease population, the risk relationships for eGFR
and albuminuria with mortality were less strong than in the
other three populations, but the relationships with kidney
failure were as strong as in the other populations. Analyses in
the chronic kidney disease population report lower levels of
eGFR and higher levels of albuminuria than in the other
three populations, and report highest risks for these most
extreme categories.
Strengths and limitations
The strengths of this analysis are the large number of cohorts,
including participants with a wide range of clinical and
demographic characteristics from Asia, Europe, North
America, and Oceania. The general population cohorts were
assembled from a systemic search, and supplemented by
high-risk and chronic kidney disease cohorts to increase the
number of kidney events and assess the generalizability of the
findings across varied clinical settings. Uniform definitions of
study populations, outcomes, predictors, covariates, and
methods for regression analysis were used in individual and
group-level meta-analysis, including testing for interactions.
The pooled relative risks were qualitatively consistent across
the study populations and across cohorts within study
populations.
However, there are important limitations. By necessity, the
results include only the outcomes that have been studied. The
meta-analyses focus primarily on relative risk. Other
important metrics, such as population prevalence, absolute
risk and attributable risk have not been modeled. It was
necessary to use different reference ranges for different
outcomes and for different populations. The analyses of
results from high-risk and chronic kidney disease popula-
tions may be affected by bias in selecting the cohorts for
inclusion in the meta-analyses and bias in selecting
participants for inclusion in the cohorts. There are also
important measurement issues, which may affect the validity
of results from each cohort and harmonization across
cohorts. These issues include the use of single measurements
for eGFR and albuminuria, the calibration of serum
creatinine assays, estimation of GFR using the MDRD Study
equation, uniformity of urine albumin assay, reliability of
spot urine samples and total urine protein for ascertainment
of albuminuria, and independent effects of urine creatinine
on mortality and kidney outcomes. Finally, there was
substantial quantitative heterogeneity in the point estimates
for the observed pooled relative risks, which requires
additional investigation.
THE PROPOSED REVISIONS AND IMPLICATIONS
On the basis of the review of the data and discussions in
plenary and breakout sessions, the five questions about the
definition and classification (Box 1) were rephrased and an
additional question was added about emphasizing the
cause of disease in addition to the stage (Table 4). For
the definition, the consensus (42/3 majority) was not to
change the eGFR threshold or the urine ACR threshold
Table 3 | Adjusted relative risks for mortality and kidney
disease outcomes stratified by age for eGFR of 45–59ml/min
per 1.73m2 in the categorical meta-analysesa
Age o65 years Age 465 years
Outcomes
Adjusted hazards
ratio or odds
ratio (95%
confidence
interval)b
Adjusted hazard
ratio or odds
ratio (95%
confidence
interval)b
All cause mortality 1.9 (1.4–2.5) 1.2 (1.0–1.5)
Cardiovascular disease
mortality
1.3 (0.6–3.2) 1.4 (1.2–1.8)
Kidney failure (ESRD) 3.1 (1.1–8.3) 3.4 (1.6–7.2)
Acute kidney injury 1.8 (1.4–2.2) 2.0 (1.8–2.3)
Kidney disease progression 2.5 (0.8–8.1) 3.4 (1.9–5.9)
Abbreviations: ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular
filtration rate; ESRD, end-stage renal disease.
aIncludes general population cohorts with ascertainment of albuminuria by ACR for
mortality and by ACR or dipstick for kidney disease outcomes.
bFor mortality, comparison is for the group with eGFR 45–59ml/min per 1.73 m2 and
urine ACR o10mg/g or dipstick negative to the reference group with eGFR
90–105ml/min per 1.73 m2 and urine ACR o10mg/g or dipstick negative. For
kidney outcomes, comparison is for the group with eGFR 45–59ml/min per 1.73m2
and urine ACRo30mg/g or dipstick 1+ or greater to the reference group with eGFR
460ml/min per 1.73m2 and urine ACR o30mg/g or dipstick negative or trace.
Table 4 | The proposed revisions (answers to questionsa)
Classification
Emphasize cause of disease as well as stage Agree
Albuminuria stages at all GFR stages (three stages) Agree
Subdivide stage 3 (at 45ml/min per 1.73 m2) Agree
Combine stages 1–2 Disagree
Definitions
Age modification for GFR threshold Disagree
Retain GFR threshold at 60ml/min per 1.73 m2 Agree
Age modification for albuminuria as a marker for
kidney damage
Disagree
Retain albuminuria threshold 30mg/g Agree
Abbreviation: GFR, glomerular filtration rate.
aAll answers represented at least a 2/3 majority vote.
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for albuminuria as marker of kidney damage. For the
classification, the consensus was to add three albuminuria
stages at all GFR stages, to subdivide stage 3 at eGFR of
45 ml/min per 1.73 m2, and to emphasize the clinical
diagnosis in addition to GFR and albuminuria stages. The
endorsement of the current definition and the revisions to
the classification system based on prognosis have important
implications.
First, the robust association of the eGFR and albuminuria
thresholds used for the current definition, with increased risk
for mortality and kidney outcomes, has implications for
research. The increased risk for all outcomes for eGFR
o60 ml/min per 1.73 m2 without consistent age interactions
is not consistent with the interpretation by others that
decreased GFR with aging is ‘normal’ or ‘physiological.’
The increased risk for all kidney outcomes for urine ACR
of 30–299 mg/g is not consistent with the interpretation
by others that ‘microalbuminuria’ is only a marker for
increased cardiovascular disease risk. More research is
necessary to understand the role of aging and systemic
vascular disease in the pathogenesis of decreased GFR and
increased albuminuria.
Second, the revised classification (Table 5) is consistent
with recommendations for the clinical evaluation and
treatment of chronic kidney disease.1 Although, the classifi-
cation system identifies many possible combinations of eGFR
and urine ACR for each clinical diagnosis, it is unlikely that
the clinical action plan would include unique recommenda-
tions for each combination. It will be important for future
research and clinical practice guidelines to evaluate and
recommend clinical action plans for groups of categories
according to risk.
Third, the ‘heat map’ generated by a composite ranking of
relative risks enhances communication about prognosis
(Figure 6). The colors indicate groups of patients at
progressively higher risk for the major outcomes. Clinicians,
researchers and the public health agencies can use these risk
categories to describe and prioritize efforts for patients and
populations. Similar communication tools are used for
description of cardiovascular disease risk.32
Fourth, because the chronic kidney disease definition is
not altered, prevalence estimates based on eGFR and urine
ACR will not change. However, an examination of the
Table 5 | Proposed revised chronic kidney disease
classification (KDIGO 2009)
Clinical Diagnosis
GFR stages
(ml/min per 1.73 m2)
Albuminuria stages
(ACR, mg/g)
Diabetes 490 o30
Hypertension 60–89
Glomerular disease 45–59 30–299
Many others 30–44
Transplant 15–29 4300
Unknown o15
Abbreviations: ACR, albumin-to-creatinine ratio; GFR, glomerular filtration rate;
KDIGO, Kidney Disease: Improving Global Outcomes.
Composite ranking for
relative risks by GFR
and albuminuria
(KDIGO 2009)
Albuminuria stages,
description and range (mg/g)
A1 A2 A3
Optimal and
high-normal
High
<10 300 –1999 2000
GFR
stages,
descrip-
tion and
range
(ml/min
per
1.73 m2)
G1 High and
optimal
>105
90 –104
G2
75 –89
60 –74
G3a Mild-
moderate 45 –59
G3b Moderate-
severe
30 –44
G4 Severe 15 –29
G5 Kidneyfailure <15
Very high and
nephrotic
10 –29 30 –299
Mild
Figure 6 |Composite Ranking for Relative Risks by glomerular filtration rate (GFR) and Albuminuria (Kidney Disease: Improving
Global Outcomes (KDIGO) 2009). As in Figure 5, colors reflect the ranking of adjusted relative risk. The ranks assigned in Figure 5
were averaged across all five outcomes for the 28 GFR and albuminuria categories. The categories with mean rank numbers 1–8 are green,
mean rank numbers 9–14 are yellow, mean rank numbers 15–21 are orange, and mean rank numbers 22–28 are red. Color for twelve additional
cells with diagonal hash marks is extrapolated based on results from the meta-analysis of chronic kidney disease cohorts. The highest level of
albuminuria is termed ‘nephrotic’ to correspond with nephrotic range albuminuria and is expressed here as X2000mg/g. Column and row
labels are combined to be consistent with the number of estimated GFR (eGFR) and albuminuria stages agreed on at the conference.
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prevalence according to the groups used for this analysis
allows clearer focus on the cells in which there is most
concern for overdiagnosis of chronic kidney disease. Whereas
there had been debate about the prognostic significance of
stage 3 comprising 4.7% of the US population (Figure 2),
with the proposed revised classification, this uncertainty is
now focused more narrowly on GFR stage 3a (45–59 ml/min
per 1.73 m2) with urine ACR o10 mg/g, comprising only
1.8% of the US population (Figure 7). Nonetheless, this is an
important group, especially in the elderly, in whom reduction
in GFR without elevated albuminuria is common and the
incidence rates for mortality and kidney outcomes, particu-
larly acute kidney injury, are high.
Fifth, these results suggest that both eGFR and albumi-
nuria should be included in the development of risk-
prediction instruments. Prediction of risk in chronic kidney
disease will be most useful if it is specific for each specific
outcome, such as mortality and kidney outcomes, and it is
likely to vary according to the clinical diagnosis.33 The
importance of covariates, such as age, sex, race, cardiovas-
cular disease risk factors, and clinical cardiovascular disease,
is also likely to vary for different outcomes. Although not
examined at this conference, it seems likely that individuals
with eGFR just above and urine ACR just below the threshold
values for the definition of chronic kidney disease will be at
increased risk for new-onset of chronic kidney disease. Better
tools for risk prediction can be helpful to clinicians in making
decisions about medical care for individual patients, to
researchers in focusing efforts on interventions to reduce risk,
and to public health agencies in monitoring the burden of
chronic kidney disease.
CONCLUSIONS AND PERSPECTIVES
In summary, the willingness and enthusiasm of a large
number of investigators worldwide to collaborate and analyze
their data according to a predefined strategy has resulted in a
unique database that provides strong epidemiological
evidence for the association of eGFR and albuminuria with
a broad spectrum of important clinical outcomes. These data
allowed the generation of a much more solid evidence base
for the debate about the definition and classification of
chronic kidney disease than has previously been available,
and resulted in a consensus among a large, international
group of clinical nephrologists and scientists. Even without a
revision of the definition, the consensus on revising the
classification indicates the need for an update to the KDOQI
clinical practice guidelines on chronic kidney disease1,2 and
KDIGO has already established a workgroup to develop a
global guideline. The individual and pooled analyses of the
collaborative research effort will be available to the work-
group, with the ongoing assistance of members of the
Analytic Team. Although the conference focused on prog-
nosis, a guideline must take all aspects and implications
of definition and classification into account, and must
consider a broader constituency of stakeholders. Ultimately,
the goal of improving global outcomes depends on successful
implementation of the updated guidelines worldwide. The
value of this or any other proposal for the definition and
classification for chronic kidney disease should be judged
based on its ability now and in the future to guide medical
care and improve global outcomes.
Another outcome of the Conference is the launch of a new
research venture, the Chronic Kidney Disease Prognosis
Consortium. The Consortium is uniquely suited for ongoing
research efforts. At this time, 45 cohorts have agreed for
ongoing participation. Publication of separate detailed
reports of the meta-analyses as original investigations in this
issue of Kidney International 20–22 and elsewhere23 represents
completion of the first phase of its research plan. Additional
analyses using new GFR-estimating equations, gender and
additional age interactions, and alternative definitions for
kidney disease progression are planned. A long-term goal
includes development of clinically applicable risk-prediction
instruments for the onset, progression, and complications of
chronic kidney disease. The KDIGO Consensus Conference
highlights how clinical practice guideline development and
implementation can stimulate research to improve outcomes
in chronic kidney disease.
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APPENDIX
Cohort representatives
Action in Diabetes and Vascular Disease: preterAx
and diamicroN-MR Controlled Evaluation (ADVANCE)
Study: Mark Woodward, PhD, Australia; African American
Study of Kidney Disease and Hypertension (AASK) Cohort
Kidney International (2011) 80, 17–28 27
AS Levey et al.: Chronic kidney disease: definition, classification, and prognosis pub l i c fo rum
Study: Jackson Wright, MD, PhD, USA; Age, Gene, Environ-
ment, Susceptibility (AGES)-Reykjavik Study: O´lafur Sku´li
Indrijason, MD, MHS and Runolfur Palsson, MD,
Iceland; Alberta Kidney Disease Network (AKDN): Brenda
Hemmelgarn, MD, PhD; Canada; Atherosclerosis Risk in
Communities (ARIC): Josef Coresh, MD, PhD and Kunihiro
Matsushita, MD, PhD, USA; Australian Diabetes, Obesity and
Lifestyle (AusDiab)Study: Robert Atkins, MD and Kevan
Polkinghorne, MBChB, MClinEpi, PhD, Australia; Beaver
Dam CKD Study: Anoop Shankar, MD, PhD, USA; Beijing
Cohort Cohort: HaiYan Wang, MD and Fang Wang, MD,
China; Canadian Care Prior to Dialysis (CAN-CARE):
Adeera Levin, MD, Canada; Canadian Prevention of Renal
and Vascular Endpoints trial (Can-Prevent): Brendan Barrett,
MD, Canada; Cardiovascular Health Study (CHS): Michael
Shlipak, MD, MPH, USA; Cholesterol and Recurrent
Events Study (CARE): Marcello Tonelli, MD, Canada; CKD
and mortality risk in older people: a community-based
population study in the UK (MRC Older People): Dorothea
Nitsch, MD, MSc and Paul Roderick, MD, UK; Chronic Renal
Impairment in Birmingham (CRIB) Study: David Wheeler,
MD, FRCP, UK; Chronic Renal Insufficiency Cohort (CRIC)
Study: Mahboob Rahman, MD, USA; Control of Blood
Pressure and Risk Attenuation Study (COBRA): Tazeen Jafar,
MD, MPH, Pakistan; ESTHER Study: Dietrich Rothenbacher,
MD, MPH, Germany; Framingham Heart Study: Caroline
Fox, MD, MPH, USA; Gubbio Population Study: Massimo
Cirillo, MD, Italy; Health Study of Nord Trøndelag (HUNT):
Stein Hallan, MD, PhD, Norway; Kaiser Pacific Northwest:
Developing a Risk Equation to Predict Mortality and
Progression to End Stage Renal Disease: David Smith, RPh,
MHA, PhD and Jessica Robin Weinstein, MD, USA; Kaiser
Permanente—Hawaiian Cohort: Brian Lee, MD, Honolulu,
USA; Kidney Early Evaluation Program (KEEP): Alan
Collins, MD and Joseph Vassalotti, MD, USA; MASTER-
PLAN: Jack Wetzels, MD, PhD, The Netherlands; Mild to
Moderate Kidney Disease (MMKD) Study: Florian Kronen-
berg, MD, Austria; Modification of Diet in Renal Disease
(MDRD) Study: Mark Sarnak, MD, MS, USA; Multi-Ethnic
Study of Atherosclerosis (MESA): Michael Shlipak, MD,
MPH, USA; Multiple Risk Factor Intervention Trial
(MRFIT): Areef Ishani, MD, MS,USA; NephroTest: Marc
Froissart, MD, PhD and Benedicte Stengel, MD, PhD, France;
National Health and Nutrition Examinations Survey
(NHANES III): Brad Astor, PhD, USA; Ohasama Study
Cohort: Hirohito Metoki, MD, PhD, Japan; USA; Okinawa
General Health Maintenance Association (OGHMA) and
Okinawa Dialysis Study (OKIDS) Registry: Kunitoshi Iseki,
MD, Japan; ONgoing Telmisartan Alone and in Combination
With Ramipril Global Endpoint Trial (ONTARGET) /
Telmisartan Randomised AssessmeNt Study in ACE iNtoler-
ant subjects with cardiovascular Disease (TRANSCEND)
Study: Johannes Mann, MD, Germany; ORFAN Follow-up
Study (OFUS): Marie Evans, MD, Sweden; Pima Indian
Longitudinal Study of Diabetes and Its Complications:
Robert Nelson, MD, PhD, USA; Prevention of Renal and
Vascular End-stage Disease Study (PREVEND): Paul E de
Jong, MD, PhD; Ron T Gansevoort, MD, PhD; and Marije
van der Velde, The Netherlands; Predictors of End Stage
Renal Disease in Patients with Type 1 Diabetes and
Proteinuria: Andrzej Krolewski, MD, PhD, USA; Prevalence
and Progression of Chronic Kidney Disease in Veterans: Ann
O0Hare, MD, USA; Ramipril Efficacy In Nephropathy (REIN
and REIN2): Annalisa Perna, Stat.Sci.D, Italy; Rancho
Bernardo Study: Simerjot Jassal, MD, USA; RENAAL Study:
Dick de Zeeuw, MD, PhD, The Netherlands; Renal - REasons
for Geographic And Racial Differences in Stroke (REGARDS)
Study: William McClellan, MD, MPH; Paul Muntner, PhD;
and David Warnock, MD, USA; Severance Cohort Study: Sun
Ha Jee, PhD, MPH, Korea; STENO Diabetes Center Study:
Peter Rossing, MD, DMSc, Denmark; Taiwan Cohort: Chi-
Pang Wen, MD, MPH, DrPH and Sung-Feng Wen, MD, USA;
Tromso Study: Bjørn Odvar Eriksen, MD, PhD, Norway;
Uppsala Longitudinal Study of Adult Men: Johannes A¨rnlo¨v,
MD, PhD, Sweden; Zwolle Outpatient Diabetes Project
Involving Available Care (ZODIAC): Henk Bilo, MD, PhD,
FRCP and Hanneke Joosten, MD, Netherlands.
Other participants
Dennis Andress, MD, USA; Shaila Basavappa, MSc, Dphil,
USA; Jeffrey Berns, MD, FACP, FACN, USA; Eric Cantor,
MD, USA; Brian Copley, MD, USA; Garabed Eknoyan, MD;
USA; Armand Famiglietti, USA; Ali Hariri, MD, USA; Alan
Hull, MD, USA; Eynu Imai, MD, PhD, Japan; Nathan Levin,
MD, USA; Alison MacLeod, MB ChB, MD, UK; Donal
O0Donoghue, MB ChB, UK; Miguel Riella, MD, PhD,
Brazil; Michael Rocco, MD, MSCE, USA; Robert Schrier,
MD, USA; Paul Stevens, MBBS, BSc, UK; Nihad AM Tamimi,
MD, UK; Yusuke Tsukamoto, MD, Japan; Katrin Uhlig, MD,
MS, USA; Anil Upadhyay, MD, UK; Raymond Vanholder,
MD, PhD, Belgium; Desmond Williams, MD, PhD, USA;
Dan Wilson, MD, USA; Christopher Winearls, MB, FRCP,
Dphil, UK.
28 Kidney International (2011) 80, 17–28
pub l i c fo rum AS Levey et al.: Chronic kidney disease: definition, classification, and prognosis
